With an effort to augment its pipeline of future products, the United States based drug maker Eli Lilly and Co has announced plans to disclose deals and acquisitions worth about one deal worth between $1 billion to $5 billion every quarter in 2020. This was said by the chief financial officer of the company in a media interview.
The company’s CFO John Smiley said that the focus of the deals will primarily be on acquiring earlier stage opportunities over a range of its core therapeutic areas including oncology, pain, immunology, and neurology. These comments were made by the CFO on the sidelines of at the JP Morgan Healthcare conference in San Francisco earlier this week.
In recent years, a number of deals have been made by Eli Lilly with an eye to increase products and sales in some of the core franchises even as the company faces challenges because of the increasing competition being faced by its older blockbuster medicines, such as diabetes treatment Humalog. There is also completion from generic manufacturers of the medicines which has resulted in lowered prices.
A deal to acquire dermatology products maker DermiraInc for $1 billion was announced by the company last week. Dermira's experimental treatment for atopic dermatitis, a serious form of eczema, which is in late-stage testing, will be accessed by the company through the deal. It will also gain access to an approved medicated cloth to treat excessive armpit sweating.
"We are looking at Dermira-like opportunities targeting assets in the $1 billion to $5 billion range," Smiley said. "We'd like to be doing something in the range of one per quarter or so."
A number of deals for cancer companies were announced by the company in 2018 and 2019. Those deals included the $8 billion acquisition of Loxo Oncology. The first commercial drug by Loxo – Vitrakvi, which has the potential to treat a range of cancers that are caused by a rare genetic mutation, was approved by regulators in the United States in 2018.
The company will make some deal in the cancer segment but will also seriously consider acquisitions in other therapeutic areas as well, Lilly Chief Executive David Ricks had said in a presentation to investors earlier this week.
Shareholders have the most opportunity in in drugs in earlier stages of development, said Smiley, even though the company has said that it would look into acquisitions with drugs in their late-stage of trials.
He added that licensing agreements, outright acquisitions, or other structures would be included in the deals.
A higher-than-expected profit for 2020 was forecast by the company in its most recent earnings call. The company said that this would be made possible by a growing demand for its newer medicines which includes diabetes drug Trulicity and Taltz for psoriasis and other related autoimmune diseases.
However, high rebates and discounts drugmakers pay to middlemen so that the medicines are available to the patients has affected the sales of Trulicity and other newer medicines.
(Source:ww.nasdaq.com)
The company’s CFO John Smiley said that the focus of the deals will primarily be on acquiring earlier stage opportunities over a range of its core therapeutic areas including oncology, pain, immunology, and neurology. These comments were made by the CFO on the sidelines of at the JP Morgan Healthcare conference in San Francisco earlier this week.
In recent years, a number of deals have been made by Eli Lilly with an eye to increase products and sales in some of the core franchises even as the company faces challenges because of the increasing competition being faced by its older blockbuster medicines, such as diabetes treatment Humalog. There is also completion from generic manufacturers of the medicines which has resulted in lowered prices.
A deal to acquire dermatology products maker DermiraInc for $1 billion was announced by the company last week. Dermira's experimental treatment for atopic dermatitis, a serious form of eczema, which is in late-stage testing, will be accessed by the company through the deal. It will also gain access to an approved medicated cloth to treat excessive armpit sweating.
"We are looking at Dermira-like opportunities targeting assets in the $1 billion to $5 billion range," Smiley said. "We'd like to be doing something in the range of one per quarter or so."
A number of deals for cancer companies were announced by the company in 2018 and 2019. Those deals included the $8 billion acquisition of Loxo Oncology. The first commercial drug by Loxo – Vitrakvi, which has the potential to treat a range of cancers that are caused by a rare genetic mutation, was approved by regulators in the United States in 2018.
The company will make some deal in the cancer segment but will also seriously consider acquisitions in other therapeutic areas as well, Lilly Chief Executive David Ricks had said in a presentation to investors earlier this week.
Shareholders have the most opportunity in in drugs in earlier stages of development, said Smiley, even though the company has said that it would look into acquisitions with drugs in their late-stage of trials.
He added that licensing agreements, outright acquisitions, or other structures would be included in the deals.
A higher-than-expected profit for 2020 was forecast by the company in its most recent earnings call. The company said that this would be made possible by a growing demand for its newer medicines which includes diabetes drug Trulicity and Taltz for psoriasis and other related autoimmune diseases.
However, high rebates and discounts drugmakers pay to middlemen so that the medicines are available to the patients has affected the sales of Trulicity and other newer medicines.
(Source:ww.nasdaq.com)
Homepage
Send to a friend
Printable version
Share
